Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
暂无分享,去创建一个
Min Gao | Anna Persson | D. Grasela | A. Persson | T. Marbury | E. Lawitz | R. Nettles | M. Gao | M. Bifano | Eric Lawitz | E. Chung | Marc Bifano | Richard E. Nettles | Ellen Chung | Thomas C. Marbury | Ronald Goldwater | Michael P. DeMicco | Maribel Rodriguez‐Torres | Apinya Vutikullird | Ernesto Fuentes | Juan Carlos Lopez‐Talavera | Dennis M. Grasela | J. Lopez‐Talavera | Apinya Vutikullird | R. Goldwater | M. Demicco | M. Rodríguez-Torres | E. Fuentes | J. López-Talavera
[1] D. Harnois. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial , 2011 .
[2] A S Perelson,et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.
[3] Tara L. Kieffer,et al. Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C , 2007, Hepatology.
[4] Tom Chu,et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial , 2010, The Lancet.
[5] Mark Harris,et al. Hepatitis C virus NS5A: tales of a promiscuous protein. , 2004, The Journal of general virology.
[6] G. Everson,et al. 1189 ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN PRODUCES HIGH RATES OF EXTENDED RAPID VIROLOGIC RESPONSE IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS: PHASE 2A TRIAL , 2010 .
[7] E. Schiff,et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial , 2010, The Lancet.
[8] G. Dusheiko,et al. P70 Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV Treatment-Naïve patients: final results of phase 3 ADVANCE Study , 2011, Gut.
[9] S. Zeuzem,et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. , 2006, Gastroenterology.
[10] A. Kwong,et al. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. , 2008, Current opinion in pharmacology.
[11] Alan S. Perelson,et al. Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .
[12] Min Gao,et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect , 2010, Nature.
[13] M. Ghany,et al. Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.
[14] Min Gao,et al. Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System , 2010, Antimicrobial Agents and Chemotherapy.